AI-generated analysis. Always verify with the original filing.
Lyell Immunopharma, Inc. furnished its press release dated March 12, 2026, under Item 2.02 regarding results of operations via Exhibit 99.1. This disclosure provides key financial information relevant to investors.
Event Type
Disclosure
Mandatory
Variant
8-K
, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release Dated March 12, 2026 104 Cover Page Interactive Data File (embedde